Antitumour effects of a protease inhibitor, nelfinavir, in hepatocellular carcinoma cancer cells

GeckoProteins Exert Anti-Tumor Effect against Cervical Cancer Cells Via PI3-Kinase/Akt Pathway

“…Indeed, all of these events are well-known to be involved in cell survival, proliferation and apoptosis. Especially, it has recently been reported that the protease inhibitors or inhibition of the proteases are critical for anti-tumor efficacy of the drugs against certain cancers such as the colon cancer [19,20] or liver cancer [21]. Thus, tryptase-inhibitor in GP, which were identified in this study may be a good candidate as a safe and efficient anti-cancer drug against the cervical cancer although the further functional study may be required.…”

Therapeutic Potential of Neem Synthesized Silver Nanoparticles on Human Gastric Cancer Cells <i>in Vitro</i>

“…To know the effect of Ag-nps in oxidative stress, the catalse activity was measured. As shown in Figure 8, the catalase activity was lower in Ag-nps treated cancer cells than the untreated control gastric cancer cells in vitro since the antioxidant enzymes are inducible, the levels of the antioxidant enzymes reflect the levels of their substrates, the active oxygen species [88] [89]. Reactive oxygen species (ROS) synthesis in gastric cells [90] [91], and ROS enhances the expression of oncogenes, stimulates cell proliferation and plays an important role in all stages of carcinogenesis [92].…”

Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial

“…In addition to our own work, there have been a number of preclinical studies demonstrating antitumor effects of NFV in dozens of cancer cell lines representing a broad range of cancer subtypes, including hepatocellular, breast, head and neck, and prostate carcinomas; multiple myeloma; glioblastoma multiforme; liposarcoma, and others . In spite of these promising preclinical studies, the efficacy of NFV as a cancer monotherapy has, to our knowledge, never been demonstrated in a clinical trial.…”

“…In addition to our own work, there have been a number of preclinical studies demonstrating antitumor effects of NFV in dozens of cancer cell lines representing a broad range of cancer subtypes, including hepatocellular, breast, head and neck, and prostate carcinomas; multiple myeloma; glioblastoma multiforme; liposarcoma, and others. 6,[13][14][15][16][17][18] In spite of these promising preclinical studies, the efficacy of NFV as a cancer monotherapy has, to our knowledge, never been demonstrated in a clinical trial. Likewise, a large retrospective multicenter study of patients with HIV (an at risk population for multiple cancers) undergoing NFV therapy did not show significantly different cancer incidence rates compared to non-NFV treated patients.…”